Illumina getting ready to buy Genomic Health
A bid for GHDX will eventually materialize, from the U.S. or overseas, which is why the stock seems to have a floor under it in the $25-27 range, where the Baker Bros. initiated recent buying after the post-election downdraft.
Essentially, you are saying you overheard speculative conversation in a restaurant, and probably not bonafide discussions related to M&A activity by ILMN brass. That speculation may become reality. After all, GHDX has a war chest of cash ($120m) and no debt. Drivers for growth/revenue in 2013 with Onco Dx for prostate, which will be huge.
Sentiment: Buy